Oncology Medications


EXKIVITY now available from Onco360!

EXKIVITY(mobocertinib) is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Dosage Form and Strength1

EXKIVITY is available as 40 mg capsules in 120-count pill bottles (NDC 63020-040-12). 

Dosage and Administration

The recommended dose of EXKIVITY is 160 mg (4 capsules) orally once daily with or without food.

For complete details, visit Exkivity

How to Order


Call 877-662-6633.


Download the Oral Rx
Oncology Order Form and
fax it to 877-662-6355.
Oral Order Form


e-Prescribe to Onco360 in Louisville, KY 40223, or NPI# 1437577988 under the retail tab in your EMR/EHR or standalone e-prescribing application.

1EXKIVITYPrescribing Information: Takeda Pharmaceuticals America, Inc. EXKIVITY.com accessed 9/21. EXKIVITYis a trademark of Takeda Pharmaceuticals International AG.